Jasper Therapeutics' Upcoming March Investor Conferences
Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company, focuses on the innovative development of briquilimab. This novel antibody therapy targets c-Kit (CD117) to address mast cell driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. The company is excited to announce its participation in several notable investor conferences in March.
TD Cowen 45th Annual Healthcare Conference
Dates: March 3-5, 2025
Presentation Date/Time: Monday, March 3, 2025, at 1:20 p.m. EST
Presentation Format: Live Presentation
Barclays 27th Annual Global Healthcare Conference
Conference Dates: March 11-13, 2025
H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Dates: March 27, 2025
Presentation Date/Time: Thursday, March 27, 2025, at 12:30 p.m. EST
Presentation Format: Live Presentation
Live Webcasts Available
Investors and interested parties can access live webcasts of these presentations on Jasper Therapeutics' Investor Relations website. Additionally, an archived replay of each presentation will be available for 30 days following the live event, ensuring that stakeholders can stay informed about the company's insights and progress.
About Jasper Therapeutics
Jasper Therapeutics is committed to developing briquilimab as a cutting-edge therapeutic option for patients with chronic mast cell diseases. The therapy is a targeted aglycosylated monoclonal antibody, working to block stem cell factor from binding to the c-Kit receptor. By effectively inhibiting signaling through this receptor, briquilimab disrupts critical survival signals, leading to apoptosis of mast cells. This process is vital for addressing the underlying causes of inflammatory responses in disorders such as CSU, CIndU, and asthma.
Current clinical studies of briquilimab are underway, demonstrating promising efficacy and safety profiles in both patients with mast cell driven diseases and healthy volunteers. Positive outcomes have been noted in clinical trials specific to CSU and CIndU, boosting Jasper's confidence in the therapy's potential.
Recent Developments
As Jasper Therapeutics approaches these significant conferences, the company continues to advance its clinical studies, aiming for regulatory approvals that will enhance the future of treatment options in mast cell driven diseases. Jasper is dedicated to making meaningful strides in the biotechnology field, ensuring that patients have access to innovative therapies that effectively manage their conditions.
Contacts for Further Information
For investor inquiries, Alex Gray can be reached at 650-549-1454 or via email at agray@jaspertherapeutics.com. Joyce Allaire from LifeSci Advisors is also available for investor-related questions at 617-435-6602 or jallaire@lifesciadvisors.com. Lauren Walker represents media inquiries, reachable at 646-564-2156 or lbarbiero@realchemistry.com.
Frequently Asked Questions
What is briquilimab?
Briquilimab is a novel antibody therapy developed by Jasper Therapeutics, designed to target mast cell driven diseases.
When will Jasper present at investor conferences?
Jasper will participate in three key conferences during March 2025, including the TD Cowen and Barclays healthcare conferences.
What diseases does briquilimab aim to treat?
Briquilimab targets chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.
How can I view the conference presentations?
Live webcasts of the presentations will be available on Jasper's Investor Relations website, with archived replays accessible for 30 days post-event.
Who should I contact for more information?
For investment-related inquiries, contact Alex Gray at agray@jaspertherapeutics.com. For media inquiries, you can reach out to Lauren Walker at lbarbiero@realchemistry.com.
